Last reviewed · How we verify
Methamphetamine Hydrochloride Tablets
Methamphetamine hydrochloride is a sympathomimetic amine that increases the release and blocks the reuptake of dopamine and norepinephrine in the central nervous system, enhancing alertness and focus.
Methamphetamine hydrochloride is a sympathomimetic amine that increases the release and blocks the reuptake of dopamine and norepinephrine in the central nervous system, enhancing alertness and focus. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy, Exogenous obesity (historical indication, rarely used).
At a glance
| Generic name | Methamphetamine Hydrochloride Tablets |
|---|---|
| Also known as | Desoxyn |
| Sponsor | Oregon Health and Science University |
| Drug class | Sympathomimetic amine; central nervous system stimulant |
| Target | Dopamine transporter (DAT); norepinephrine transporter (NET); trace amine-associated receptor 1 (TAAR1) |
| Modality | Small molecule |
| Therapeutic area | Neurology; Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Methamphetamine acts as a potent stimulant by promoting the release of catecholamines (dopamine and norepinephrine) from presynaptic neurons and inhibiting their reuptake, leading to increased synaptic concentrations. This mechanism results in enhanced central nervous system stimulation, increased wakefulness, improved attention, and appetite suppression. The drug crosses the blood-brain barrier readily due to its lipophilic nature, making it highly potent.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD)
- Narcolepsy
- Exogenous obesity (historical indication, rarely used)
Common side effects
- Insomnia
- Nervousness/anxiety
- Headache
- Palpitations/tachycardia
- Appetite suppression
- Tremor
- Dizziness
Key clinical trials
- Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder (PHASE3)
- Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users (PHASE2)
- Why Wait? Initiating Contingency Management in Traumatically Injured Patients During Hospitalization (NA)
- Drugs Brain and Behavior (DDP) (EARLY_PHASE1)
- Effects of Genotype on Resting State Connectivity During Methamphetamine Administration (PHASE4)
- Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function (EARLY_PHASE1)
- Safety Interaction Trial Ibudilast and Methamphetamine (PHASE1)
- N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |